Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.

• Phase: Phase 4

Details

• Lead Sponsor: Arrowhead Regional Medical Center
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• any patient 18 years of age or older with a primary pterygium that extends at least 2 mm past the limbus

Exclusion Criteria:

• history of glaucoma

• previous ocular surgery

• steroid-response glaucoma

• previous myocardial infarct

• bleeding disorder

• pregnancy

• lack of patient cooperation